Non-GLP Toxicology and Safety Pharmacology Studies



Gain maximum confidence for regulatory submissions through our range of Non-GLP Toxicology and Safety Pharmacology studies.

- Comprehensive NHP Non-GLP Toxicology assay platform, for evaluating drug physiological and pathological effects.
 - Assess compounds across healthy lean or spontaneously diabetic, dysmetabolic, and obese NHPs.
 - Utilize a range of common administration routes (i.v., i.m., s.c., p.o.) as well as intraocular and intraperitoneal injections, and intrathecal administration.
 - Broad assessment program including blood, tissue, and organ collection, biopsy, and gross necropsy over a wide range of body systems, as well as a variety of assay and parameter collections. Tissue homogenization and *in vitro* assays available.
- Non-GLP Toxicology rodent platform utilizing commercially available rodent models.
 - Complemented by studies in highly translatable models of Type 2 diabetes (ZDSD rat, MS-NASH mouse (formerly FATZO)) and PKD (pcy mouse).
 - Main study endpoints of necropsy, gross organ weight, and fixation for histology or rtPCR.
- Safety Pharmacology rodent and NHP platforms, for standalone assessments or integrated toxicological profiling.
 - Covering cardiovascular, hepatic, metabolic, and renal/urinary systems.
 - High definition data determined by continuous monitoring of cardiovascular and metabolic assessments (BP, HR, glucose levels).
- Rapid study initiation for fast turnaround of robust results.
- AAALAC certified, highly trained staff with extensive experience providing client confidence with data and regulatory submissions.







Schedule Scientific Consultation

Request a consultation to discuss your project. consultation@crownbio.com



DiscoverCrown

Trial translational rodent and NHP models for obesity, diabetes, renal disease, and NAFLD/NASH. crownbio.com/discovercrown